EHA and EBMT join forces in the GoCART coalition to advance cellular therapy in Europe.
The field of cell and gene therapy is one of the most exciting developments in medicine, raising hopes and posing new challenges.
The EHA and the EBMT, the two leading European societies in the field of hematology and stem cell transplantation, announced a strategic partnership to empower Europe to become a global leader in the cellular therapy field for hematological diseases, joining forces and bringing their collective resources and expertise to the newly founded GoCART coalition.
Advancing the field of cell and gene-based therapies requires progress on multiple fronts, including creating a pre- and post-authorization registry to monitor product safety and efficacy; harmonizing data collection, center qualification and educational requirements, and overcoming barriers in regulations designed for more traditional pharmaceutical products. To address such a wide range of complex issues, there is a need for strong collaboration amongst all relevant stakeholders.
The network is open to any relevant stakeholder, including patient representatives, health care professionals, pharmaceutical companies, health authorities, health technology assessment bodies and reimbursement agencies, European and national medical organizations and registry holders.
The first concrete activities underway include the development of a joint educational program, a multi-stakeholder review of EBMT’s cellular therapy data collection form, and harmonization of existing site qualification schemes to reduce inspection burden for hospitals. These are some of the areas that show the potential of this coalition to advance the field of gene and cellular therapies in Europe in the interests of our patients.
About the GoCART Coalition
GoCART is a multi-stakeholder coalition in the field of gene and cellular therapies manufactured from cells and tissues of hematopoietic origin. This new Coalition brings together stakeholders from across the sector, including patients, health care professionals, health authorities, HTA bodies and reimbursement agencies, pharmaceutical companies and medical non-profit organizations.
The aim of GoCART is to promote patient access to novel cellular therapies and to contribute health and well-being through innovation by multi-stakeholder collaboration on clinical data, standards of care, center qualification, education and policy.